About Vivacelle Bio

WHO WE ARE

Vivacelle Bio is a late-stage biopharma company developing life-saving treatments for shock and trauma.

The company’s lead, Phase 3 product, VBI-S, is built on its pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to elevate blood pressure in hypovolemic septic shock, a leading cause of death that impacts millions around the world.

A Phase 2 trial of VBI-S demonstrated 100% efficacy, with the treatment resulting in elevated blood pressure in hypovolemic septic shock patients who are refractory to fluid therapy.

In addition to venture capital, Vivacelle has garnered backing and financial support from the US Department of Defense and the National Institutes of Health.

Vivacelle Bio is headquartered in Kansas City, MO.